Castle Biosciences (CSTL) Assets (2018 - 2026)

Castle Biosciences has reported Assets for 9 years, with the latest figure at $561.2 million in Q2 2026.

• Quarterly Assets rose 3.02% year-over-year to $561.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $561.2 million (up 3.02% YoY) and the FY2025 annual result came in at $578.6 million, up 8.91% from the prior year.
• Assets improved to $561.2 million in Q2 2026 per CSTL's latest filing, from $547.8 million in the prior quarter.
• Over five years, Assets peaked at $578.6 million in Q4 2025 and troughed at $425.4 million in Q2 2023.
• A 5-year average of $491.0 million and a median of $472.9 million in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2023 and 2024: Assets slipped 7.19% in 2023, then advanced 18.01% in 2024.
• Over 5 years, Assets stood at $447.3 million in 2022, then climbed by 1.34% to $453.3 million in 2023, then increased by 17.18% to $531.2 million in 2024, then advanced by 8.91% to $578.6 million in 2025, then declined by 3.0% to $561.2 million in 2026.
• According to Business Quant data, Assets over the past three periods registered $561.2 million, $547.8 million, and $578.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.